Home
Clinical Trials
Nimotuzumab in Combined With ...

Nimotuzumab in Combined With Paclitaxel and Cisplatin for Treatment of Metastatic Esophageal Squamous Cell Carcinoma

Last Updated: 2016-02-01

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE3

Total Enrollment

504 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-11-30

Study Completion Date

2019-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This clinical study is designed as a phase 3,multicenter, double-blind, randomized, controlled study,to evaluate the efficacy and safety of nimotuzumab combined with paclitaxel+cisplatin（TP) compared with TP as first-line treatment for the metastatic esophageal squamous carcinoma.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Nimotuzumab Plus Paclitaxel and Cisplatin as 1st Line Treatment for Esophageal Squamous Cell Cancer

NCT01336049

Esophageal Squamous Cell Cancer

UNKNOWN PHASE2

A Phase III Study of Nimotuzumab Plus Concurrent Chemoradiotherapy in Loco-regional Esophageal Squamous Cell Carcinoma

NCT02409186

Prosthesis Survival

UNKNOWN PHASE3

Nimotuzumab,Camrelizumab, and Neoadjuvant Chemotherapy（nCT） in the Treatment of Esophageal Squamous Cell Carcinoma

NCT07312578

Esophageal Squamous Cell Carcinoma

ENROLLING_BY_INVITATION PHASE2

Nimotuzumab Combined With Sintilimab and Chemotherapy for Advanced Esophageal Squamous Cell Carcinoma

NCT06718205

Esophageal Cancer

RECRUITING PHASE2

Nimotuzumab in Combination With Chemoradiation for Local Advanced Esophageal Squamous Cell Carcinoma

NCT01232374

Squamous Cell Carcinoma

UNKNOWN PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This clinical study is designed as a phase 3,multicenter, double-blind, randomized, controlled study,to evaluate the efficacy and safety of nimotuzumab combined with TP compared with TP as first-line treatment for the metastatic esophageal squamous carcinoma.The main endpoint is OS.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Esophageal Squamous Cell Carcinomas

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

experimental group

Nimotuzumab+TP(paclitaxel+cisplatin)

Group Type EXPERIMENTAL

Nimotuzumab

Intervention Type DRUG

400mg,day1,weekly,until disease progression or toxicity

Paclitaxel

Intervention Type DRUG

175mg/m\^2,for 3 hour(Peripherally Inserted Central Catheter,PICC),day1,21 days for a cycle ,until disease progression or toxicity，maximum duration is 6 cycles.

Cisplatin

Intervention Type DRUG

60mg/m\^2,day1，21 days for a cycle ,until disease progression or toxicity,maximum duration is 6 cycles.

control group

Placebo + TP(paclitaxel+cisplatin)

Group Type PLACEBO_COMPARATOR

Paclitaxel

Intervention Type DRUG

175mg/m\^2,for 3 hour(Peripherally Inserted Central Catheter,PICC),day1,21 days for a cycle ,until disease progression or toxicity，maximum duration is 6 cycles.

Cisplatin

Intervention Type DRUG

60mg/m\^2,day1，21 days for a cycle ,until disease progression or toxicity,maximum duration is 6 cycles.

Placebo

Intervention Type DRUG

400mg,day1,weekly,until disease progression or toxicity

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Nimotuzumab

400mg,day1,weekly,until disease progression or toxicity

Intervention Type DRUG

Paclitaxel

175mg/m\^2,for 3 hour(Peripherally Inserted Central Catheter,PICC),day1,21 days for a cycle ,until disease progression or toxicity，maximum duration is 6 cycles.

Intervention Type DRUG

Cisplatin

60mg/m\^2,day1，21 days for a cycle ,until disease progression or toxicity,maximum duration is 6 cycles.

Intervention Type DRUG

Placebo

400mg,day1,weekly,until disease progression or toxicity

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Paclitaxel Injection Cisplatin for Injection Nimotuzumab Placebo

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Voluntary and sign a consent form;
2. Age≥18 years;
3. Histological diagnosis as metastatic esophageal squamous cell carcinoma, including: (1)Naked metastatic esophageal cancer：have no opportunity to receive any radical surgery or radical radiation therapy (2) recurrent metastatic esophageal cancer：recurrence after surgery or adjuvant radiotherapy or radical concurrent radio or radiochemotherapy,haven't received systemic chemotherapy and have measurable lesions outside radiotherapy target zone(3) recurrent metastatic esophageal cancer,more than 6 months after neoadjuvant or adjuvant chemotherapy;
4. When patients need to receive palliative radiotherapy,the palliative radiotherapy should complete over 4 weeks and target lesions should outside the radiotherapy target zone(radiotherapy lesions include but not limited to primary tumors, bone, lymph nodes);
5. According to RECIST 1.1 criteria, at least one measurable lesion exist;
6. Expected survival time is over 3 months;
7. Eastern Cooperative Oncology Group（ECOG）0 or 1;
8. Normal bone marrow and hematopoietic function;total bilirubin acuities≤1.5×Upper Limit Of Normal（ULN）, creatinine≤1.0×ULN, aspartate aminotransferase（AST）/alanine aminotransferase（ALT）≤2.5×ULN, ALP≤5.0×ULN, creatinine clearance \> 60 ml/min, liver metastases patients: AST/ALT≤5.0×ULN;
9. Take effective contraceptive measures when in growth period;
10. Compliance is good.

Exclusion Criteria

1. Have received any palliative chemotherapy for metastatic esophageal cancer
2. Recurrence or metastasis after neoadjuvant chemotherapy or postoperative adjuvant \< 6 months;
3. Received any kinds of radiotherapy within 4 weeks;
4. Patients who can received palliative radiotherapy and all lesions are in one radiation zone;
5. Had received adjuvant/neoadjuvant therapy and have used paclitaxel within 6 months;
6. Had received adjuvant/neoadjuvant therapy and the cumulative dose of cisplatin was over 300 mg/m2;
7. Alone or combined with brain metastasis;
8. No measurable tumor lesions;
9. Combined with other primary malignant tumors (except cured skin basal cell carcinoma and cervical carcinoma in situ);
10. Allergy to the component of investigational drugs;
11. Patients who are receiving the treatment of chronic or multiple doses of corticosteroids (inhaled steroids or short-term oral cortisol according to the clinical indications were allowed);
12. Haven't recovered to degree 1 from the toxicity of treatment before.
13. Concomitant with severe cardiovascular diseases, such as uncontrol heart failure, coronary heart disease, cardiomyopathy, arrhythmia,high blood pressure or history of myocardial infarction within 5 years;
14. Concomitant with serious complications, such as the activity of the digestive tract hemorrhage, perforation, severe jaundice, gastrointestinal obstruction, active clinical infection (\> 2 levels of infection standard);
15. With chronic diarrhea disease and renal insufficiency;
16. Have disease affecting cognition or mental abnormal;
17. Have other severe acute or chronic diseases;
18. Pregnancy or lactation women;
19. Have participated in other clinical trials within 30 days.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Lin Shen, Dr

Role: STUDY_CHAIR

Peking University Cancer Hospital & Institute

Locations

Explore where the study is taking place and check the recruitment status at each participating site.